Background: HER2 activation in tumours supports multiple signalling pathways, including those regulating invasion and metastasis. Among the involved genes, Tyrosine and Dual Specificity Phosphatases (PTPs and DSPs) may play a relevant, though not completely clear role.
Introduction
The HER2 receptor controls cell proliferation and motility [1] [2] [3] and its mutations or amplification have been related to solid tumours, including breast, ovary, lung, prostate and colon cancers [4, 5] . The role of HER2 in ovary cancer is less understood [6] . However, poor prognosis is linked to tumour spreading beyond the ovaries, an event requiring enhanced motility. Since HER2 controls motility, it is conceivable that its upregulation contributes to motility in ovary cancer cells. HER2 up-regulation is accompanied by alteration of a number of genes, including protein kinases [1] . Conversely, few data exist on Tyrosine phosphatases (PTPs) and Dual-Specificity phosphatases (DSPs) and the existing studies generally focused on posttranslational regulation [7] , as we discussed elsewhere [8] .
Thirty eight PTPs, 21 receptor and 17 soluble, and approximately 65 DSPs are found in the human genome. DSPs include MKPs, SSH, PTP4A, cdc14, PTEN, Myotubularins, CDC25 and EYA. PTPs and DSPs contribute to control cell proliferation, adhesion and migration, differentiation and survival [7, 9] . They may not only terminate the action of protein kinases, hence behaving like anti-oncogenes (e.g., the DUSPs/MKPs that dephosphorylate MAPKs [10] ) but also transduce positive signals, likewise the case of PTPN11 [11] , PTPN1 [12] , PTPRE [13] and cdc25 [14] . In the HER2 signaling, negative regulation was reported for PTPN18 [15] , whereas a favoring role was documented for PTPN11 [16] and PTPN1 [17] . Little is known of their role in ovary cancer, particularly in the HER2-overexpressing type, highly motile at some stages [6] . It is conceivable that the PTPs and DSPs present in motility pathways may have a role in the motility sustained by HER2.
PTPN12 (PTP-PEST) [18] is a critical regulator of cell adhesion, migration and cell-cell junction, interacting with cytoskeletal and signalling proteins, such as small GTPases, FAK, CAS, paxillin, src, abl, and others [19] [20] [21] [22] . PTPN12 generally behaves like a negative regulator of motility, but in ras-activated cells it was also reported to promote migration through the inhibition of FAK [23] . Several aspects of the PTPN12 mechanism are still unclear, particularly concerning its substrates in different cell types. For instance, src, a PTPN12 substrate in migration and growth factor signalling, is activated by PTPN12 in osteoclasts [24] and inactivated in intestinal cells [25] .
FAK is both an enzyme and a platform which recruits signalling molecules to the focal adhesions [26] [27] [28] , and is often altered in cancer cells [29] . During migration FAK undergoes cycles of activation/inactivation and changes at its multiple phosphorylation sites [26, 28] . Several PTPs and some DSPs are regulated during migration [9] . In addition to PTPN12, studies indicated roles for PTPN11 [11, 25] and PTPD1 [30] in the regulation of FAK and src. In past investigations we found that FAK S910 was phosphorylated by ERK5 and involved in cell shaping and motility [31] , whereas FAK S722 was phosphorylated by GSK3-␤ during fibroblasts adhesion and late migration [32] . Both sites were dephosphorylated by the PP1δ isoform [31, 32] .
Several members of the MAP kinase family [33] regulate motility [28, 34] . ERK1/2 was reported to phosphorylate FAK S910 in fibroblasts, in response to growth factors and stress stimuli [35] or ras activation [23] . Conversely, we found that FAK S910 was phosphorylated by ERK5 in cells stimulated with phorbol ester [31] . More recently the involvement of ERK5 in motility was further supported by its activation in integrin-mediated epithelial cell attachment [36] , keratinocyte migration [37] and focal contact turnover [38] . Generally ERK5 is activated downstream of receptor tyrosine kinases [39] , including HER2 in breast cancer cells [40] .
This study investigates the expression of PTPs and DSPs in SKOV-3 cells, a highly motile, HER2-overexpressing ovary carcinoma cell line. HER2 was silenced and the expression analysis adopted a DNA microarray, targeting all the PTPs and DSPs of the human genome [8] . PTPN12, displaying the most significant alteration, was further analysed. The results identified: a) PTPN12 as a negative regulator of SKOV-3 cell motility, through the control of FAK phosphorylation at Y397 and its down-modulation by HER2, and b) the HER2-dependent regulation of FAK phosphorylation at S910 through the activation of ERK5, altogether unravelling new aspects of the complex cross-talk between HER2 and the motility machinery.
Materials and methods

Antibody sources
Antibodies were purchased as follows: FAK, pY576/577 of FAK, src, PTPN6 (SHP1) and PTEN (Santa Cruz Biotech); pS722, pS910 and pY397 of FAK (BioSource); HER2, ERK5, PTPN12 (PTP-PEST), AKT, pS473 of AKT and pY418 of src (Cell Signaling Biotech); ERK1/2, pERK1/2 (pT202/pY204 of ERK1 and pT185/pY187 of ERK2) and ␣ tubulin (Sigma Aldrich); PTPRK (Abcam); PTPN11 (SHP2) (Upstate). The anti-CDC25C antibodies were produced as described [41] .
Cell culture, treatment and extract
SKOV-3 cells (originally from ATCC and re-characterized at the Istituto Nazionale Tumori, Milan, Italy) were grown in RPMI added with 10% fetal calf serum (Sigma Aldrich) [32] . In one experiment subconfluent cells were exposed to the MEK inhibitor UO126 (Calbiochem), diluted in DMSO, or to DMSO alone (control). For extraction, cells were washed twice in cold PBS and lysed in 50 mM TRIS-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 % Triton X-100, 7.5 mM 2-mercaptoethanol (lysis buffer), added with 1 mM orthovanadate, 50 mM NaF and protease inhibitors (0.02% benzamidine, 0.02 % PMSF, 0.02%, TPCK, 10 g/ml soybean trypsin inhibitor and 4 g/ml leupeptine), followed by centrifugation at 4 • C and immediate use or storage at −80 • C.
RNAi silencing
Cells were transfected with the shRNAmir vectors targeting human HER2 or PTPN12, or with the empty vector, as control (Open Biosystems), using Lypophectamine 2000 as transfection reagent (Invitrogen). Cells were grown and selected in the presence of 5 g/ml puromycin starting from 24 h after transfection. Cells were further grown and subcloned by dilution in the presence of puromycin and analyzed for the presence of the targeted protein by immunoblotting; cells displaying sub-total gene silencing were further grown and used in the experiments.
DNA array
Custom oligo GEArray, displaying 60-mer oligonucleotide probes, targeting 103 PTPs and DSPs and 5 housekeeping genes (RPS27A, GAPDH, B2 M, HSP90AB1 and ACTB) were produced by SABiosciences. cRNA (2 g) was used for overnight hybridization, followed by peroxidase-based chemiluminescence detection on X-ray films, according to the manufacturer 's instructions. Data extraction, normalization with the indicated housekeeping genes and analysis used the GEArray Expression Analysis Suite (SABiosciences). Expression levels are given as the ratios of treated to control cells. To boost the results reliability, only changes greater than 30 % were reported [8] .
Cell proliferation assay
Cells were seeded as specifically indicated, grown for 48 h, washed in PBS, fixed in 3% paraformaldehyde and 2% sucrose in PBS, pH 7.5, for 10 min at room temperature, stained with Crystal Violet and lysed in 10% (v/v) acetic acid. Optical density of the lysate was then measured at 595 nm.
In vitro cell migration into a wounded area and transwell assay
The scratch-wound and transwell assays were performed as described previously [32] . Migration was assessed on stained cells by calculating the percentage of wound closure (i.e., the distance moved by the cells) with respect to the 100% open wound (time 0).
Immunoprecipitation, electrophoresis and immunoblotting
Immunoprecipitation with Protein A-or Protein G-Sepharose (Sigma Aldrich), electrophoresis and immunoblotting were performed as described previously [32] . For immunoblot quantification, the PTP or DSP protein bands from treated and control cells were analyzed by densitometric scanning and normalized to the ␣-tubulin band analyzed in the same experiment (i.e., the PTP or DSP/␣-tubulin value ratios were calculated). Normalized data from different experiments were averaged, as specifically indicated. Results are given as percent of averages from control cells.
In-gel tyrosine phosphatase assay
The phosphatase activity of cell lysates or associated with immunoprecipitated FAK was assayed using the substrate 32 P-labeled poly-Glu-Tyr, introduced into a 10% polyacrylamide-SDS gel [42] . The gel was immediately used to run the samples (mixed with Laemmli buffer). This was followed by fixing, phosphatase renaturation and substrate dephosphorylation during overnight incubation, as indicated by the original method [43] . Subsequently, the gel was stained with Coomassie brilliant blue, dried and subjected to autoradiography to detect active phosphatases, indicated by dephosphorylated areas of discrete Mr. PTPN12 identification was based on: a) the Mr of the active phosphatase (around 120 k), a broad band, due to degradation of its PEST-sequence [21] ; b) immunodetection of PTPN12 in samples run in parallel with the gel for the activity assay (see Fig. 4A ); c) band enrichment in anti-PTPN12 immunocomplexes (not shown).
ERK5 and FAK kinase assays
ERK5 was assayed using either the ERK5-specific substrate Mef2, as described previously [31, 44] or myelin basic protein (MBP). For MBP kinase, ERK5 was first immunoprecipitated from 0.5 mg of cell extract, additionally washed with 25 mM imidazole, pH 7.5, and incubated with 20 g MBP at 30 • C for 15 min. All the rest was as indicated for Mef2 kinase, apart from control assays, that were either prepared with unrelated IgGs or without MBP. FAK was assayed following immunoprecipitation, as described previously [32] . The reaction, containing 2.5 mg/ml poly-Glu-Tyr (Sigma Aldrich), 0.6 M PP2 (src inhibitor, Tocris) and 0.5 mM orthovanadate (all the rest was as indicated for the MBP kinase) was run for 20 min at 30 • C and terminated by spotting 40% of the mix on Whatman P81 chromatography paper (2 × 1 cm), followed by extensive washing in 10 mM H 3 PO 4 and counting in a ␤-scintillation counter. The kinase activity was calculated after subtracting the cpm of control immune complexes, prepared with unrelated IgGs.
Results
HER2 sustains cell motility
To find if HER2 sustains motility, we prepared SKOV-3 cells carrying stable HER2-silencing. Such cells displayed about 70% decrease in HER2 protein with respect to control cells and decrease in the activity of two members of HER2 signalling, ERK1/2 and AKT, based on the marked decrease in their phosphorylated active forms (pERK1/2 and pAKT, Fig. 1A ). Concomitantly, also cell proliferation decreased (measured at 48 h from cell plating, Fig. 1B ). HER2 silencing impaired migration, whether assessed through wound-healing assay (Fig. 1C) or trans-well assay (Fig. 1D) .
Although both migration results are bound to be influenced by the decreased proliferation, the effect of HER2 silencing on migration was so marked (see e.g., 12 h, Fig. 1C ) that cannot be explained by the mere decrease in cell number. Altogether, the results indicated that HER2 contributed to sustain SKOV-3 cell motility. The subsequent results, indicating the involvement of FAK and other cell motility molecules, confirmed this hypothesis.
HER2 affects the expression of several PTPs and DSPs, and primarily of PTPN12
Since several Tyrosine Phosphatases (PTPs) and Dual-Specificity Phosphatases (DSPs) play a role in the HER2-dependent signalling and might mediate the HER2-driven motility pathways, we investigated whether the expression of any of these was affected by HER2. For this purpose we adopted a custom DNA microarray, displaying all the 103 human PTPs and DSPs (designed for a previous investigation, [8] ) and analysed the changes consequent to HER2 silencing. Four PTPs and 5 DSPs were found up-regulated (2-3-fold), whereas DUSP4 was strongly down-regulated in HER2-silenced cells (Fig. 2A) . Since RNA changes are not necessarily followed by protein changes, we analysed the protein level of all the altered PTPs and of some of the altered DSPs (guided by the availability of reliable antibodies). Only PTPN12 (PTP-PEST) was highly increased in HER2-silenced cells, with respect to control cells. Also PTPN11 (SHP2) displayed some increase, whereas PTPRK, PTPN6, PTEN and CDC25C were unchanged ( Fig. 2B and C) . Based on the remarkable change and the involvement of PTPN12 in migration, we set to investigate whether its HER2-driven down-modulation may sustain the motility of SKOV-3 cells.
PRPN12 depresses cell migration
In order to learn more about its role in SKOV-3 cells, PTPN12 was silenced. Stable silencing induced over 80% decrease in PTPN12 protein (Fig. 3A and B) and enhanced migration, whether assessed through woundhealing assay (Fig. 3C) or trans-well assay (Fig. 3D) . Morphological changes, such as cell detachment and rounding, were also observed (not shown). On the other hand, PTPN12-silencing did not affect cell proliferation (not shown). The results defined PTPN12 as a negative regulator of SKOV-3 cell migration. This, in turn, may support the hypothesis that downmodulation of PTPN12 by HER2 enhances migration and contributes to the motility of SKOV-3 cells.
PTPN12 affects FAK phosphorylation at Y397 and FAK activity
To investigate the PTPN12 mechanism, we focused on FAK, a key regulator of cell adhesion and motility. In a preliminary test, we assessed the ability of PTPN12 to associate with FAK in control SKOV-3 cells. The results indicated that PTPN12 co-immunoprecipitated with FAK and within this complex PTPN12 was active, based on in-gel activity assay (Fig. 4A) . The phosphorylation of the FAK autophosphorylation site Y397, a major regulator of FAK activity [26, 28] , was much lower in HER2-silenced cells than in control cells (Fig. 4B) , supporting the hypothesis that PTPN12 dephosphorylates Y397, thus inactivating FAK. The decrease in FAK activity was confirmed by direct kinase activity assay of immunoprecipitated FAK (Fig. 4C) . On the other hand, in PTPN12-silenced cells the level of pY397 and FAK kinase activity were similar to control cells ( Fig. 4B and C) . This result does not account for the increased motility of the PTPN12-silenced cells (Fig. 3C and D) , hence the contribution of other FAK sites, including some analysed further on, should be taken onto account. As a potential PTPN12 target, we examined also FAK Y576/577, sites phosphorylated by src. The phosphorylation of Y576/577 was higher in HER2-silenced than in control cells, hence opposite to what one might expect for a PTPN12 target (Fig. 4B) . The reliability of the result was confirmed by the concomitant activation of src, indicated by the increased src pY418 (Fig. 4B) (phosphorylation of FAK Y576/577 is considered a good indicator of src activation [45] ). Conversely, in PTPN12-silenced cells pY576/577 was low, again in agreement with the detected src inactivation (low pY418, Fig. 4B ). A possible explanation for src activation in spite of HER2 silencing might be that these poorly motile cells are also more adherent than control cells, a condition that justifies src activation. Altogether, the results suggested targeting of FAK Y397 by PTPN12 and excluded Y576/577.
HER2 affects FAK phosphorylation at S910 and S722, in quiescent or migrating cells
Several other phosphorylation sites contribute to FAK regulation in motility. In previous investigations we addressed the role of two FAK sites: S910, linked to cell shape and motility [31] , and S722, responding to cell adhesion and migration [32] . S910 displayed decreased phosphorylation in HER2-silenced cells, whereas it was close to control level in PTPN12-silenced cells. On the other hand, pS722 was little affected in quiescent cells (Fig. 4B) .
The FAK sites were also analysed in cells induced to migrate in a wounded area. Though migration increased the phosphorylation of FAK Y397 in all cell types, the phosphorylation levels were much lower in HER2-silenced cells at all time-points. This result agrees with the data obtained in quiescent cells (Fig. 4B ) and with the decreased motility displayed by HER2-silenced cells (Fig. 1C and D) . Also pS910 was confirmed to be lower in HER2-silenced cells and increased in migrating HER2-silenced and PTPN12-silenced cells, suggesting motility-linked regulation. On the other hand its level was constantly high in control cells, a fact that is possibly explained by the activation of ERK5 (see further on and Discussion). pS722 was constantly low in HER2-silenced cells, further stressing the migration impairment. On the other hand, pS722 increased in control and PTPN12-silenced cells, confirming the increase in pS722 during late migration that we previously described in fibroblasts [32] . Finally, ERK1/2, which is stimulated during migration (see pERK1/2 in control cells), was less activated in migrating HER2-silenced cells than in control or PTPN12-silenced cell (Fig. 4D) . Altogether the results indicated alteration of several phosphorylation sites that may contribute to impair migration in HER2-silenced cells (displaying high PTPN12) and to sustain migration in PTPN12-silenced cells (displaying high HER2). The most intriguing changes concerned S910, a site that was further investigated.
ERK5 targets S910 of FAK in HER2-dependent way
FAK S910 was reported to be a target for either ERK1/2 or ERK5 [31, 35] . In our system either kinase might be involved, since HER2 silencing affected ERK1/2 ( Fig. 1A and 4D ) and ERK5 is known to be stimulated by HER2 [40] . To discriminate between these two kinases we used the MEK inhibitor U0126. Blot analysis of lysates from SKOV-3 cells treated with 1 or 10 M U0126 indicated that ERK1/2 was completely inactivated at both inhibitor concentrations, whereas S910 was still phosphorylated (Fig. 5A) . While ruling-out ERK1/2, the results suggested the involvement of ERK5, which is much less sensitive to U0126 than ERK1/2 [31, 46] . To test this hypothesis, ERK5 was silenced in SKOV-3 cells. Stable silencing was confirmed by almost complete loss of ERK5, detected as both protein and kinase activity, assayed with the ERK5-specific substrate Mef2 [31] (Fig. 5B and C; the inset of Fig. 5B shows one set of the autoradiography data used to generate the bar-graph). Loss of pS910 in ERK5-silenced cells (Fig. 5C ) clearly indicated that S910 phosphorylation was due to ERK5.
The subsequent step was aimed to assess if also the ERK5 activity was affected by HER2-silencing. The ERK5 kinase assay indicated a significant ERK5 inactivation in HER2-silenced cells (Fig. 5D) . As an additional test, we adopted the alternative substrate myelin basic protein to assay the kinase activity of immunoprecipitated ERK5. The results confirmed ERK5 inactivation in HER2-silenced cells ( Fig. 5D ; the insets show one set of the autoradiography data used for the bar-graph). Finally, the ERK5 protein level was not affected by HER2-silencing (Fig. 5D , inset), indicating that ERK5 inactivation was due to posttranslational regulation.
Discussion
Most of the studies on PTPs and DSPs in HER2 signalling focused on post-translational regulation, whereas here we investigated their expression alterations linked to HER2 modulation. The highly motile SKOV-3 cells were adopted to identify PTPs and DSPs potentially involved in motility pathways. The results supported the hypothesis that HER2 activation affects the expression of several PTPs and DSPs, based on the detected up-modulation of 4 PTPs (PTPK, PTPN6, PTPN11, PTPN12) and 5 DSPs (PTEN, MTMR3, SBF1, CDC25C, ACP1) and down-modulation of DUSP4 in HER2-silenced cells. Moreover, the 4 PTPs and some of the DSPs (PTEN, DUSP4, ACP1) are rel-evant to cell adhesion or migration, further supporting the hypothesis of their involvement in mediating the HER2-driven cell motility.
In a previous investigation, a similar analysis in human HER2 breast cancer and HER2-overexpressing MDA-MB-453 breast cancer cells identified several altered PTPs and DSPs. Among these, DUSP6, CDC25B and MTMR1 were altered in both tumours and cells, hence potentially contributing to HER2-driven tumorigenesis [8] . We also proposed that DUSP6, up-modulated in breast tumours at a level comparable to ERBB2, might represent a new breast tumour marker or a potential therapy target. Comparison with the present results indicates that the altered PTPs and DSPs identified in the breast and ovary studies show only few overlaps (PTPN11, PTEN and CDC25C), which may indicate the specificity of the results obtained and suggests differential HER2 roles in the two systems.
The role of PTPN12 in motility has been studied in fibroblasts, but is much less defined in epithelial cells, though recent reports involved PTPN12 in the motility of pancreatic and intestinal carcinoma cells [22, 23] . In our system, comparison of HER2-silenced and PTPN12-silenced cells indicated almost symmetrical behaviours. HER2-silencing impaired migration and up-regulated PTPN12, whereas PTPN12-silencing (on an HER2 up-regulated background) enhanced migration and induced morphological changes, suggesting cytoskeletal rearrangements. This brought to propose that HER2-overexpression depresses PTPN12, contributing, in turn, to the marked motility of SKOV-3 cells. Dephosphorylation of FAK by PTPN12 was reported also in fibroblasts, but in this case it occurred in cells induced to migrate by activated ras [23] . On the contrary, in our system migration induced increase in Y397 phosphorylation, whereas loss of phosphate at Y397 occurred in HER2-silenced cells, which are less motile. We conclude that targeting of Y397 by PTPN12 might be a general mechanism, but the cells analysed as well as the migration cues may account for the marked differences reported by the two studies.
Analysis of FAK phosphorylation at S910 uncovered the role of ERK5 and excluded ERK1/2, although both kinases are controlled by HER2 ( Fig. 1A and  5D ; see also [40] ). In HER2-silenced SKOV-3 cells, pS910 decreased in parallel with the decrease in ERK5 activity and FAK inactivation, suggesting the involvement of the phosphorylation of S910 by ERK5 in the control of FAK. Also the increase in pS910 during the migration of HER2-silenced and PTPN12-silenced cells suggested that this site is regulated during motility. On the other hand, in control cells pS910 was constantly high and did not change in migration. This might be explained by assuming that the high, HER2-dependent ERK5 activity induced a pS910 level that could not be increased any further. An alternative possibility is the involvement of the phosphatase PP1δ that targets pS910 [31] and associates with FAK at focal adhesions [47] , but whose regulation during migration is still unknown. In a previous investigation we reported that FAK S910 was phosphorylated by ERK5 in fibroblasts and breast carcinoma cell lines. Treatment with the phorbol ester TPA increased pS910 and induced morphological changes suggesting cytoskeletal rearrangements [31] . More recently the involvement of ERK5 in adhesion and migration was indicated in keratinocytes [37] and endothelial cells [38] . Connection between ERK5 and FAK was also reported in cell adhesion to vitronectin, however indicating that ERK5 was activated downstream of FAK [36] , hence depicting a mechanism different from the one described herein.
Among the altered PTPs, also PTPN11 (SHP2) displayed up-regulation and protein increase in HER2- Fig. 6 . Proposed contribution of PTPN12 and ERK5 to the HER2-directed cell migration. FAK phosphorylation at Y397 and S910 by PTPN12 and ERK5, in control and HER2-silenced SKOV-3 cells, and consequences on FAK activity and cell migration. The arrow thickness defines low (thin arrow) or high (thick arrow) enzyme activity. silenced cells. PTPN11 generally transduces a positive signal and enhances ERK activation in growth factor pathways, including those evoked by HER2 (e.g., in breast cancer cells [48] ). However, its role in integrating receptor and integrin signals is not completely clear due to conflicting results (e.g., with respect to FAK and src regulation [11] ). Our results indicate a negative control of PTPN11 by HER2 in SKOV-3 cells, suggesting, in turn, negative control of motility and a possible cooperation with PTPN12 that would deserve further investigation.
Altogether, the results suggest the ability of PTPN12 and ERK5 to mediate the HER2-driven cell motility in SKOV-3 cells, through FAK targeting (Fig. 6 ). This may represent a new aspect of the complex cross-talk between HER2 and the migration machinery required for normal cell life and tumour invasion. A better understanding of the regulation of specific genes (e.g., kinases and phosphatases) linked to enhanced motility in tumour cells, may lead to identify new tumour markers. These, in turn, might help to predict invasiveness and metastatic potential already in primary tumours. Within this picture, valuable information may come also from the analysis or generation of cell lines with varying metastatic abilities. All these issues seem to be specifically relevant in the case of cancers, including ovarian cancers, that become highly metastatic at some stages.
